REVIEW

JOURNAL OF
MEDICAL VIROLOGY WILEY

Potential interventions for novel coronavirus in China: A systematic review

Lei Zhang | Yunhui Liu

Department of Neurosurgery, Shengjing
Hospital of China Medical University,
Shenyang, Liaoning, China

Correspondence
Yunhui Liu, Department of Neurosurgery,
Shengjing Hospital, China Medical University,
No. 36 Sanhao Street, Heping, Shenyang,
110004 Liaoning, China.
Email: liuyh@sj-hospital.org

Abstract

An outbreak of a novel coronavirus (COVID-19 or 2019-CoV) infection has posed significant threats to international health and the economy. In the absence of treatment for this virus, there is an urgent need to find alternative methods to control the spread of disease. Here, we have conducted an online search for all treatment options related to coronavirus infections as well as some RNA-virus infection and we have found that general treatments, coronavirus-specific treatments, and antiviral treatments should be useful in fighting COVID-19. We suggest that the nutritional status of each infected patient should be evaluated before the administration of general treatments and the current children's RNA-virus vaccines including influenza vaccine should be immunized for uninfected people and health care workers. In addition, convalescent plasma should be given to COVID-19 patients if it is available. In conclusion, we suggest that all the potential interventions be implemented to control the emerging COVID-19 if the infection is uncontrollable.

KEYWORDS
2019-CoV, coronavirus, COVID-19, MERS, potential interventions, SARS

1 | INTRODUCTION

Coronaviruses (CoVs) belong to the subfamily *Orthocoronavirinae* in the family of *Coronaviridae* in the order *Nidovirales*, and this subfamily including α-coronavirus, β-coronavirus, γ-coronavirus, and delta-coronavirus.[1] Coronaviruses primarily cause enzootic infections in birds and mammals and, in the last decades, have shown to be capable of infecting humans as well.[2] The outbreak of severe acute respiratory syndrome (SARS) in 2002 and Middle East respiratory syndrome (MERS) in 2012 has demonstrated the lethality of coronaviruses when they cross the species barrier and infect humans.[2] SARS-CoV and MERS-CoV all belong to the β-coronavirus family.[3] Recently, a novel flu-like coronavirus (COVID-19) related to the MERS and SARS coronaviruses was found at the end of 2019 in China[4,5] and the evidence of human-to-human transmission was confirmed among close contacts.[6] The genome of COVID-19 is a single-stranded positive-sense RNA.[7] The sequence analysis showed that the COVID-19 possessed a typical genome structure of coronavirus and belonged to the cluster of β-coronaviruses including SARS-CoV and MERS-CoV.[7] COVID-19 was more than 82%

identical to those of SARS-CoV.[8,9] COVID-19 may spread worldwide with the pandemic. Currently, there is no registered treatment or vaccine for the disease. In the absence of a specific treatment for this novel virus, there is an urgent need to find an alternative solution to prevent and control the replication and spread of the virus. We have done an online search on PubMed and Web of Science with the keywords of SARS, MERS, and coronaviruses. We summarize and propose therapeutic options available for the treatment of this novel coronaviruses.

2 | GENERAL TREATMENT FOR VIRAL INFECTION

2.1 | Nutritional interventions

2.1.1 | Vitamin A

Vitamin A is the first fat-soluble vitamin to be recognized and β-carotene is its plant-derived precursor (Table 1). There are three

TABLE 1 General supportive treatments

Options	Virus targeted and functions related
2.1. Nutritional interventions	
2.1.1. Vitamin A	Measles virus, human immunodeficiency virus, avian coronavirus
2.1.2. B vitamins	MERS-CoV; ventilator-induced lung injury
2.1.3. Vitamin C	Avian coronavirus; lower respiratory tract infections
2.1.4. Vitamin D	Bovine coronavirus
2.1.5. Vitamin E	Coxsackievirus, bovine coronavirus
2.1.6. Omega-3 polyunsaturated fatty acids (PUFA)	Influenza virus, human immunodeficiency virus
2.1.7. Selenium	Influenza virus, avian coronavirus; viral mutations
2.1.8. Zinc	Measles virus, SARS-CoV
2.1.9. Iron	Viral mutations
2.2. Immunoenhancers	
2.2.1. Interferons	SARS-CoV, MERS-CoV
2.2.2. Intravenous gammaglobulin	SARS-CoV
2.2.3. Thymosin α-1	Increase resistance to glucocorticoid-induced death of thymocyte
2.2.4. Thymopentin	Restore antibody production
2.2.5. Levamisole	Immunostimulant agent or immunosuppressive agent
2.2.6. Cyclosporine A	SARS-CoV, avian infectious bronchitis virus
2.2.7. Chinese medicine	SARS-CoV, avian infectious bronchitis virus

Abbreviations: MERS-CoV, Middle East respiratory syndrome coronavirus; SARS-CoV, severe acute respiratory syndrome coronavirus.

active forms of vitamin A in the body, retinol, retinal, and retinoic acid. Vitamin A is also called "anti-infective" vitamin and many of the body's defenses against infection depend on an adequate supply. Researchers have believed that an impaired immune response is due to the deficiency of a particular nutritional element.[10] Vitamin A deficiency is strongly involved in measles and diarrhea[11] and measles can become severe in vitamin A-deficient children. In addition, Semba et al[12] had reported that vitamin A supplementation reduced morbidity and mortality in different infectious diseases, such as measles, diarrheal disease, measles-related pneumonia, human immunodeficiency virus (HIV) infection, and malaria. Vitamin A supplementation also offers some protection against the complications of other life-threatening infections, including malaria, lung diseases, and HIV.[13] Jee et al[14] had reported that low vitamin A diets might compromise the effectiveness of inactivated bovine coronavirus vaccines and render calves more susceptible to infectious disease. The effect of infection with infectious bronchitis virus (IBV), a kind of coronaviruses, was more pronounced in chickens fed a diet marginally deficient in vitamin A than in those fed a diet adequate in vitamin A.[15] The mechanism by which vitamin A and retinoids inhibit measles replication is upregulating elements of the innate immune response in uninfected bystander cells, making them refractory to productive infection during subsequent rounds of viral replication.[16] Therefore, vitamin A could be a promising option for the treatment of this novel coronavirus and the prevention of lung infection.

2.1.2 | B vitamins

B vitamins are water-soluble vitamins and work as part of coenzymes. Each B vitamin has its special functions. For example,

vitamin B2 (riboflavin) plays a role in the energy metabolism of all cells. Vitamin B2 deficiency had been suspected to occur among US elderly.[17] Keil et al[18] had reported that vitamin B2 and UV light effectively reduced the titer of MERS-CoV in human plasma products. Vitamin B3, also called nicotinamide, could enhance the killing of *Staphylococcus aureus* through a myeloid-specific transcription factor and vitamin B3 was efficacious in both prophylactic and therapeutic settings.[19] Moreover, vitamin B3 treatment significantly inhibited neutrophil infiltration into the lungs with a strong anti-inflammatory effect during ventilator-induced lung injury. However, it also paradoxically led to the development of significant hypoxemia.[20] Vitamin B6 is also needed in protein metabolism and it participates in over 100 reactions in body tissues. In addition, it also plays important role in body immune function as well. As shortage of B vitamins may weaken host immune response, they should be supplemented to the virus-infected patients to enhance their immune system. Therefore, B vitamins could be chosen as a basic option for the treatment of COVID-19.

2.1.3 | Vitamin C

Vitamin C is another water-soluble vitamin and it is also called ascorbic acid, which means "no-scurvy acid." Vitamin C is best known for its role in the synthesis of collagen in connective tissues and acts as an antioxidant. Vitamin C also supports immune functions and protects against infection caused by a coronavirus.[21] For example, Atherton et al[22] had reported that vitamin C increased the resistance of chick embryo tracheal organ cultures to avian coronavirus

infection. Vitamin C may also function as a weak antihistamine agent to provide relief from flu-like symptoms such as sneezing, a running or stuffy nose, and swollen sinuses.[23] Three human controlled trials had reported that there was significantly lower incidence of pneumonia in vitamin C-supplemented groups, suggesting that vitamin C might prevent the susceptibility to lower respiratory tract infections under certain conditions.[24] The COVID-19 had been reported to cause lower respiratory tract infection, so vitamin C could be one of the effective choices for the treatment of COVID-19.

2.1.4 | Vitamin D

Vitamin D is not only a nutrient but also a hormone, which can be synthesized in our body with the help of sunlight. In addition to its role in maintaining bone integrity, it also stimulates the maturation of many cells including immune cells. A high number of healthy adults have been reported to be with low levels of vitamin D, mostly at the end of the Winter season.[25] In addition, people who are housebound, or institutionalized and those who work at night may have vitamin D deficiency, as do many elderly people, who have limited exposure to sunlight.[26] The COVID-19 was first identified in Winter of 2019 and mostly affected middle-aged to elderly people. The virus-infected people might have insufficient vitamin D. In addition, the decreased vitamin D status in calves had been reported to cause the infection of bovine coronavirus.[27] Therefore, vitamin D could work as another therapeutic option for the treatment of this novel virus.

2.1.5 | Vitamin E

Vitamin E is a lipid-soluble vitamin and it includes both tocopherols and tocotrienols. Vitamin E plays an important role in reducing oxidative stress through binding to free radicals as an antioxidant.[28] Vitamin E deficiency had been reported to intensify the myocardial injury of coxsackievirus B3 (a kind of RNA viruses) infection in mice[29] and increased the virulence of coxsackievirus B3 in mice due to vitamin E or selenium deficiency.[30] In addition, the decreased vitamin E and D status in calves also caused the infection of bovine coronavirus.[27]

2.1.6 | Omega-3 polyunsaturated fatty acids

Long-chain polyunsaturated fatty acids (PUFAs) are important mediators of inflammation and adaptive immune responses.[31] Omega-3 and omega-6 PUFAs predominantly promote anti-inflammatory and pro-inflammatory effects. They are precursors of resolvins/protectins and prostaglandins/leukotrienes, respectively.[31] Begin et al[32] had studied plasma lipids levels in patients with AIDS and had found that a selective and specific lack of the long-chain PUFAs of omega-3 series, which are found in high concentrations in fish oils. In addition,

protectin D1, the omega-3 PUFA-derived lipid mediator, could markedly attenuate influenza virus replication via RNA export machinery. In addition, treatment of protectin D1 with peramivir could completely rescue mice from flu mortality.[33] Leu et al[34] had found that several PUFAs also had anti-hepatitis C virus (HCV) activities. Therefore, Omega-3 including protectin D1, which served as a novel antiviral drug, could be considered for one of the potential interventions of this novel virus, COVID-19.

2.1.7 | Selenium

Selenium is an essential trace element for mammalian redox biology.[35] The nutritional status of the host plays a very important role in the defense against infectious diseases.[36] Nutritional deficiency impacts not only the immune response but also the viral pathogen itself.[10] Dietary selenium deficiency that causes oxidative stress in the host can alter a viral genome so that a normally benign or mildly pathogenic virus can become highly virulent in the deficient host under oxidative stress.[10] Deficiency in selenium also induces not only impairment of host immune system, but also rapid mutation of benign variants of RNA viruses to virulence.[37] Beck et al[38] had reported that selenium deficiency could not only increase the pathology of an influenza virus infection but also drive changes in genome of coxsackievirus, permitting an avirulent virus to acquire virulence due to genetic mutation.[39] It is because that selenium could assist a group of enzymes that, in concert with vitamin E, work to prevent the formation of free radicals and prevent oxidative damage to cells and tissues.[37] It was reported that synergistic effect of selenium with ginseng stem-leaf saponins could induce immune response to a live bivalent infectious bronchitis coronavirus vaccine in chickens.[40] Therefore, selenium supplementation could be an effective choice for the treatment of this novel virus of COVID-19.

2.1.8 | Zinc

Zinc is a dietary trace mineral and is important for the maintenance and development of immune cells of both the innate and adaptive immune system.[41] Zinc deficiency results in dysfunction of both humoral and cell-mediated immunity and increases susceptibility to infectious diseases.[42] Zinc supplement given to zinc-deficient children could reduce measles-related morbidity and mortality caused by lower respiratory tract infections.[43] Increasing the concentration of intracellular zinc with zinc-ionophores like pyrithione can efficiently impair the replication of a variety of RNA viruses.[44] In addition, the combination of zinc and pyrithione at low concentrations inhibits the replication of SARS coronavirus (SARS-CoV).[44] Therefore, zinc supplement may have effect not only on COVID-19-related symptom like diarrhea and lower respiratory tract infection, but also on COVID-19 itself.

2.1.9 | Iron

Iron is required for both host and pathogen and iron deficiency can impair host immunity, while iron overload can cause oxidative stress to propagate harmful viral mutations.[45] Iron deficiency has been reported as a risk factor for the development of recurrent acute respiratory tract infections.[46]

2.2 | Immunoenhancers

2.2.1 | Interferons

Interferons (IFNs) have divided into type I and Type II Interferons. As a member of Type I IFN, IFN-α is produced very quickly as part of the innate immune response to virus infection. IFN-α inhibits the replication of animal and human coronaviruses.[47,48] The investigation in vitro also demonstrated that type I interferons including IFN-β could inhibit the replication of SARS-CoV.[49] However, interferon-γ was reported not to possess antiviral activity against SARS coronavirus.[50] Kuri et al[51] further reported that IFN transcription was blocked in tissue cells infected with SARS-CoV and the cells were able to partially restore their innate immune responsiveness to SARS-CoV after priming with small amounts of IFNs. Moreover, Tan et al had tested the inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. They found that the complete inhibition of cytopathic effects of the virus was observed with specific subtypes (β-1b, α-n1, α-n3, and human leukocyte interferon α) in culture.[52] Haagmans et al[54] also reported in vivo that pegylated recombinant IFN-α2b, a registered drug for chronic hepatitis C,[53] could protect type 1 pneumocytes against SARS coronavirus infection in monkeys (macaques). The drug given at 3 days before infection could reduce viral replication and lung damage as compared with the control monkeys.[55] It was also considered as a candidate drug for SARS therapy at that time and the effectiveness of synthetic recombinant IFN-α for the treatment of SARS patients was demonstrated in a pilot clinical trial.[56] In addition, interferons have also been found to be potent inhibitors of MERS-CoV replication.[57] Moreover, the combination of interferon-α-2a with ribavirin was administered to patients with severe MERS-CoV infection and the survival of these patients was improved.[57] These findings suggest that these approved IFN's could be also used for the treatment of this novel coronavirus.

2.2.2 | Intravenous gammaglobulin

Intravenous gammaglobulin (IVIg) was first developed in the late 1970s [58] and is probably the safest immunomodulating drug available for long-term use in all ages. However, it does have adverse reactions. During the SARS outbreak in 2003, IVIg was used extensively in Singapore. However, one-third of critically ill patients developed venous thromboembolism including pulmonary embolism despite the use of low-molecular weight heparin prophylactic.[59] It was due to the IVIg-induced increase of viscosity in hypercoagulable states of SARS patients.[60]

2.2.3 | Thymosin α-1

Thymosin α-1 (Ta1) is a thymic peptide hormone and it has a peculiar ability to restore the homeostasis of the immune system.[61] It is was first isolated from thymic tissue in the mid-sixties and it had gained much attention for its immunostimulatory activity.[62] It was chemically synthesized and used in diseases where the immune system was hindered or impaired.[63] Besides its role in thymocyte development, thymosin α-1 could also increase resistance to glucocorticoid-induced death of the thymocyte.[64] Thymosin α-1 could also be used as immune enhancer to SARS patients and it was effective in controlling the spread of the disease.[65,66] Methylprednisolone was often used during the current treatment of COVID-19 and the side effect of corticoid-induced death of thymocytes should be considered. So, it is wise to use thymosin α1 before the administration of methylprednisolone.

2.2.4 | Thymopentin

Thymopentin (TP5, munox), a synthetic pentapeptide corresponding to the active site of thymopoietin, had been shown to restore antibody production in old mice.[67] Additionally, it could enhance the antibody response in humans when it was applied subcutaneously three times a week at doses of 50 mg.[68] Moreover, thymopentin could also be used as an adjuvant treatment for non-responders or hyporesponders to hepatitis B vaccination.[69]

2.2.5 | Levamisole

Levamisole, a synthetic low-molecular-weight compound, is the first member of a new class of drugs that can increase the functions of cellular immunity in normal, healthy laboratory animals.[70] However, levamisole can act as either an immunostimulant agent or an immunosuppressive agent depending upon the dosing and the timing. So, its clinical use should be carefully taken. Joffe et al[71] had reported that levamisole and ascorbic acid treatment in vitro could reverse the depressed helper/inducer subpopulation of lymphocyte in measles. Therefore, the use of levamisole could also be considered for the treatment of COVID-19.

2.2.6 | Cyclosporine A

Cyclosporine A is a very important immunosuppressive drug and it has been widely used in transplantation. The emerging use of cyclosporine A has greatly improved the survival rates of patients and grafts after solid-organ transplantation.[72] Cyclosporine A is also used for the treatment of autoimmune disorders. Luo et al[73] had speculated that nucleocapsid protein (NP) of SARS-CoV played an important role in the process of virus particle assembly and release and it might also bind to human cyclophilin A. Cyclophilin A is a key

member of immunophilins acting as a cellular receptor for cyclosporine A.[74] Cyclophilin A has played an important role in viral infection which either facilitates or inhibits their replication.[74] In addition, the inhibition of cyclophilins by cyclosporine A could block the replication of coronavirus of all genera, including SARS-CoV as well as avian infectious bronchitis virus.[75] Therefore, the non-immunosuppressive derivatives of cyclosporine A might serve as broad-range coronavirus inhibitors applicable against the emerging novel virus-like COVID-19.

2.2.7 | Chinese medicine

Glycyrrhizin is an active component of liquorice roots in Chinese medicine. Cinatl et al[76] had reported that glycyrrhizin could inhibit the replication of SARS-associated virus in vitro and it had already been suggested as an alternative option for treatment of SARS at that time. Baicalin, another Chinese herb, is a flavonoid which is isolated from Radix Scutellaria. Baicalin was also found to have the ability to inhibit SARS-CoV in vitro.[50] Ginseng stem-leaf saponins could highly enhance the specific-antibody responses for Newcastle disease virus and infectious bronchitis virus.[40] Therefore, Chinese Medicine could also be considered as a choice to enhance host immunity against the infection of COVID-19.

In summary, the general treatment for viral infection including nutritional interventions and all kinds of immunoenhancers has been used to enhance host immunity against RNA viral infections. Therefore, they may also be used to fight COVID-19 infection by correcting the lymphopenia of patients.

3 | CORONAVIRUS-SPECIFIC TREATMENTS

3.1 | Coronaviral protease inhibitors

Chymotrypsin-like (3C-like) and papain-like protease (PLP) are coronavirus encoded proteins (Table 2). They have an essential function for coronaviral replication and also have additional function for inhibition of host innate immune responses. Targeting 3C-like protease (3 CLpro) and papain-like protease (PLpro) are more attractive for the treatment of coronavirus.[77]

3.1.1 | Chymotrypsin-like (3C-like) inhibitors

Cinanserin
Cinanserin, an old drug, is well-known for serotonin receptor antagonist. It could inhibit the 3 chymotrypsin-like (3C-like) protease and was a promising inhibitor of replication of SARS-CoV.[78] The 3CLpro was also been found to be encoded in COVID-19.[7] Therefore, Cinanserin may be a better choice for the treatment of COVID-19 infection.

TABLE 2 Coronavirus-specific treatments

3.1. Coronavirus protease inhibitors
3.1.1. Chymotrypsin-like (3C-like) inhibitors
3.1.1.1. Cinanserin
3.1.1.2. Flavonoids
3.1.2. Papain-like protease (PLP) inhibitors
3.1.2.1. Diarylheptanoids
3.2. Spike (S) protein-angiotensin-converting enzyme-2 (ACE2) blockers
3.2.1. Human monoclonal antibody (mAb)
3.2.2. Chloroquine
3.2.3. Emodin
3.2.4. Promazine
3.2.5. Nicotianamine

Flavonoids
Flavonoids are an important class of natural products and have several subgroups, which include chalcones, flavones, flavonols, and isoflavones.[79] Flavonoids have many functions besides antioxidant effects and they also have antiviral abilities. Shimizu et al[80] had found that flavonoids from Pterogyne Nitens could inhibit the entry of the hepatitis C Virus. Jo et al[81] had suggested that the anti-coronavirus activity of some flavonoids (Herbacetin, rhoifolin and pectolinarin) was due to the inhibition of 3C-like protease (3CLpro). Other flavonoids (Herbacetin, isobavachalcone, quercetin 3-β-d-glucoside, and helichrysetin) were also found to be able to block the enzymatic activity of MERS-CoV/3CLpro.[82] Moreover, Ryu et al[83] had reported that biflavonoids from *Torreya nucifera* also brought inhibition effect of SARS-CoV/3CL (pro).

3.1.2 | Papain-like protease inhibitors

Papain-like protease (PLP) of human coronavirus is a novel viral-encoded deubiquitinase and is an IFN antagonist for inhibition of host innate antiviral immune response.

Diarylheptanoids
Diarylheptanoids is a natural product and is extracted from the stem bark of *Alnus japonica*. It had been found to be able to inhibit papain-like protease of SARS-CoV.[77]

Therefore, cinanserin together with flavonoids and other natural compounds could be chosen as alternative choices to fight COVID-19 infection through targeting coronaviral proteases.

3.2 | Spike (S) protein-angiotensin-converting enzyme-2 (ACE2) blockers

Angiotensin-converting enzyme-2 (ACE2) is a type I integral membrane protein which functions as a carboxypeptidase and is the first human homolog of ACE.[84] ACE2 efficiently hydrolyzes the potent vasoconstrictor angiotensin II to angiotensin (1-7) and it has been implicated in

hypertension, cardiac function, heart function, and diabetes.[84] In addition, ACE2 is also a functional receptor of SARS-CoV and it mediates virus entry into the cell through binding with spike (S) protein.[85,86] The S protein of SARS-CoV is a type I surface glycoprotein and is responsible for the binding to cellular receptors. In addition, S protein mediates the fusion of viral and host membranes.[87] Zhou et al reported that COVID-19 used ACE2 as a sole receptor for the entry, but did not use other coronavirus receptors, aminopeptidase N and dipeptidyl peptidase, for the entry. Blocking the binding of S protein to ACE2 is important for the treatment of SARS-CoV infection.[88]

3.2.1 | Human monoclonal antibody

Sui et al had found one recombinant human monoclonal antibody (mAb) (single-chain variable region fragments, scFvs 80R) against the S1 domain of S protein of SARS-CoV from two nonimmune human antibody libraries. The mAb could efficiently neutralize SARS-CoV and inhibit syncytia formation between cells expressing the S protein and those expressing the SARS-CoV receptor ACE2.[89]

3.2.2 | Chloroquine

Chloroquine is a 9-aminoquinoline known since 1934. Apart from its well-known antimalarial effects, the drug also has many interesting biochemical properties including antiviral effect. In addition, it had been used against viral infection.[90] Moreover, chloroquine was also found to be a potent inhibitor of SARS coronavirus infection through interfering with ACE2, one of cell surface binding sites for S protein of SARS-CoV.[91]

3.2.3 | Emodin

Emodin is an anthraquinone compound derived from genus *Rheum* and *Polygonum* and it is also a virucidal agent.[92] Emodin could significantly block the interaction between the S protein of SARS-CoV and ACE2. Therefore, emodin might abolish SARS-CoV infection by competing for the binding site of S protein with ACE2.[93]

3.2.4 | Promazine

Promazine, anti-psychotic drug, shares a similar structure with emodin. It has been found to exhibit a significant effect in inhibiting the replication of SARS-CoV.[94] As compared to emodin, promazine exhibited potent inhibition of the binding of S protein to ACE2. These findings suggested that emodin and promazine might be able to inhibit SARS-CoV infectivity through blocking the interaction of S protein and ACE2.[93] Therefore, the monoclonal antibody (scFv80R), chloroquine, emodin, and promazine could be used as alternative choices for the treatment of COVID-19.

3.2.5 | Nicotianamine

Nicotianamine is an important metal ligand in plants[95] and it is found a novel angiotensin-converting enzyme-2 inhibitor in soybean.[96] So, it is another potential option to be used to reduce the infection of COVID-19.

4 | ANTIVIRAL TREATMENTS

4.1 | Ribavirin

Ribavirin, a broad-spectrum antiviral agent, is routinely used to treat hepatitis C (Table 3). During the outbreak of SARS, ribavirin was used extensively for most cases with or without concomitant use of steroids in Hong Kong.[97] However, there was considerable skepticism from overseas and local experts on the efficacy of ribavirin.[98] Because there was a report mentioned that ribavirin had no significant activity against SARS-CoV in vitro[52] and the use of ribavirin was found to be associated with significant toxicity, including hemolysis (in 76%) and decrease in hemoglobin (in 49%).[99] However, Morgenstern et al[49] had reported that ribavirin and interferon-β synergistically inhibited the replication of SARS-associated coronavirus in animal and human cell lines. In view of adverse reactions and the lack of in vitro efficacy, the use of ribavirin should be seriously considered for the treatment of COVID-19, even in combination with other antiviral drugs.

4.2 | Lopinavir/ritonavir (kaletra)

The combination of lopinavir with ritonavir is widely used as a boosted protease inhibitor in the treatment of HIV infection.[100] Lopinavir (LPV) is usually combined with ritonavir (RTV) to increase lopinavir half-life through the inhibition of cytochrome P450.[101] Chu et al[102] had found that the use of LPV/RTV with ribavirin in the treatment of SARS was associated with a better outcome. Kim et al[103] had also reported a successful case of MERS-CoV disease

TABLE 3 Antiviral treatments and other compounds

4. Antiviral treatments
4.1. Ribavirin
4.2. Lopinavir (LPV)/ritonavir (RTV) (Kaletra)
4.3. Remdesivir
4.4. Nelfinavir
4.5 Arbidol
4.6. Nitric oxide
5. Other compounds
5.1. α-Lipoic acid
5.2. Estradiol and phytoestrogen
5.3. Mucroporin-M1

treated with triple combination therapy LPV/RTV, ribavirin, and IFN-α2a in South Korea. Regarding this novel virus, COVID-19, Kim's triple combination therapy should be considered as an option at the early stage of the disease.

4.3 | Remdesivir

Remdesivir (RDV), a nucleoside analog GS-5734, had been reported to inhibit human and zoonotic coronavirus in vitro and to restrain severe acute respiratory syndrome coronavirus (SARS-CoV) in vivo.[104] Recently, the antiviral activity of RDV and IFN-β was found to be superior to that of LPV/RTV-IFN-β against MERS-CoV in vitro and in vivo.[101] In addition, RDV could improve pulmonary function and reduce lung viral loads and severe lung pathology in mice, which was impossible for LPV/RTV-IFN-β.[101] Recently, a first COVID-19-infected case was reported in the United States and the use of remdesivir was administered when the patient's clinical status was getting worse.[105] Therefore, the use of RDV with IFN-β could be a better choice for the treatment of COVID-19 comparing with that of the triple combination of LPV/RTV-IFN-β. However, randomized and controlled trials are still needed to determine the safety and efficacy of remdesivir.

4.4 | Nelfinavir

Nelfinavir is a selective inhibitor of HIV protease, which is responsible for posttranslational processing of HIV propeptides.[106] Yamamoto et al[107] had found that nelfinavir could strongly inhibit the replication of SARS-CoV. Therefore, nelfinavir could also be an option for the treatment of COVID-19.

4.5 | Arbidol

Arbidol (ARB) is a Russian-made small indole-derivative molecule and is licensed in Russia and China for prophylaxis and treatment of influenza and other respiratory viral infections.[108] Arbidol had been found to be able to block viral fusion against influenza A and B viruses as well as hepatitis C virus.[109] Arbidol could also inhibit hepatitis C virus by blocking hepatitis C virus entry and replication in vitro.[110] In addition, arbidol and its derivatives, arbidol mesylate, had been reported to have antiviral activity against the pathogen of SARS in the cell cultures and arbidol mesylate was nearly 5 times as effective as arbidol in reducing the reproduction of SARS virus in the cultured cells.[111]

4.6 | Nitric oxide

Nitric oxide (NO) is a gas with diverse biological activities and is produced from arginine by NO synthases. NO is able to interact with superoxide, forming peroxynitrite, which, in turn, can mediate bactericidal or cytotoxic reactions.[112] In addition, NO had played an important role in regulating airway function and in treating inflammatory airway diseases.[113] Rossaint et al[114] reported that the beneficial effects of NO inhalation could be observed in most patients with severe acute respiratory distress syndrome. NO was also found to inhibit the synthesis of viral protein and RNA.[115] Moreover, Akerström et al[116] had reported that organic NO donor, S-nitroso-N-acetylpenicillamine, could significantly inhibit the replication cycle of SARS-CoV in a concentration-dependent manner. Therefore, the NO inhalation could be also chosen as an option for the treatment of severely COVID-19 infected patients.

5 | OTHER COMPOUNDS

5.1 | α-Lipoic acid

α-Lipoic acid (ALA), a naturally occurring disulfide compound, acts as a cellular coenzyme and has been applied for the treatment of polyneuropathies and hepatic disorders for years (Table 3).[117] ALA, as an antioxidant, has played a pivotal role in scavenging free radicals to protect against oxidative damage in several diseases.[118] In addition, ALA also had its capability to enhance intracellular glutathione (GSH) levels[118] and to normalize the oxidative stress induced by Dexamethasone in chicken.[119] Wu et al[120] also reported that the oxidative stress in host cells was an important factor in the infectivity of human coronavirus 229E and the glucose-6-phosphate dehydrogenase (G6PD) deficiency was another factor that enhanced human coronavirus 229E infection. The addition of α-lipoic acid to G6PD-knockdown cells could attenuate the increased susceptibility to human coronavirus 229E infection.[120] Interestingly, Baur et al[121] also found that α-lipoic acid was effective to inhibit the replication of HIV-1. In summary, we speculate that ALA could be also used as an optional therapy for this new virus.

5.2 | Estradiol and phytoestrogen

Females, generally, mount more robust immune responses to viral challenges than males, which can result in more efficient virus clearance.[122] Epidemiological studies showed that males experiencing a higher rate of incidence and case fatality compared with females after SARS-CoV infection.[123,124] During the MERS outbreak, the disease occurrence rate in men was almost twice as much as in women and the case fatality rate was the same as the occurrence rate among men and women.[125] In addition, Channappanavar et al had reported that male mice were more susceptible to SARS-CoV infection compared with age-matched female mice. However, the mortality was increased in female mice when the ovariectomy was done or the estrogen receptor antagonist was given.[126] Wei et al[127] also found that serum levels of prolactin, follicle-stimulating hormone, and luteinizing hormone of

SARS patients were significantly higher than those of control groups, while estradiol (E2), pregnancy hormone, and thyroid-stimulating hormone were considerably lower than those of normal controls. Interestingly, estrogenic compounds had been found to reduce influenza A virus replication in primary human nasal epithelial cells derived from female, but not male, donors.[128] In addition, resveratrol, a phytoestrogen from grape seeds and red wine, had been reported to be a potent anti-MERS agent in vitro.[129] Therefore, 17β-Estradiol or phytoestrogen could also be an alternative option to be considered for the treatment of COVID-19.

5.3 | Mucroporin-M1

Mucroporin-M1 is a scorpion venom-derived peptide and has broad-spectrum virucidal activity against many viruses including measles, influenza H5N1 viruses, and SARS-CoV.[130] Therefore, this peptide could also be used for the treatment of COVID-19 infection as well as the new drug design to target COVID-19.

6 | CONCLUSION

In this review, we summarize all the potential interventions for COVID-19 infection according to previous treatments of SARS and MERS. We have found that the general treatments are very important to enhance host immune response against RNA viral infection. The immune response has often been shown to be weakened by inadequate nutrition in many model systems as well as in human studies. However, the nutritional status of the host, until recently, has not been considered as a contributing factor to the emergence of viral infectious diseases. Therefore, we propose to verify the nutritional status of COVID-19 infected patients before the administration of general treatments. In addition, we also found coronavirus-specific treatments and antiviral treatments were very useful for the treatment of SARS and MERS. They should also be considered as potential treatments for COVID-19 infection. The other compounds should also be chosen as alternative options for the treatment as well as new drug designs.

To complete the eradication of virus infection, the COVID-19-related vaccines are warranted. The vaccine development for SARS had already attracted the attention of many scientists in the past. Avian IBV is similar to SARS-CoV and both viruses belong to coronavirus. IBV is in group 3 and SARS belongs to group 4.[131] Bijlenga et al[55] had suggested that avian live virus IBV vaccine (strain H) be used to treat SARS in 2005. However, preliminary tests in monkeys should be taken before the startup. Interestingly, children are seldom attacked by COVID-19 as well as SARS-CoV. It may be due to the required vaccine program for every child. The RNA-virus vaccines and the adjuvants in vaccine programs may help children escape from the infection. Therefore, the RNA-virus-related vaccines including measles (MeV), polio, Japanese encephalitis virus, influenza virus, and rabies-related vaccines, could be used as the most promising alternative choices to prevent human-to-human transmission through immunizing health care workers and noninfected population as well.

Recombinant measles vaccine expressing S protein of SARS and MERS were also tried by many researchers. Escriou et al[132] had generated live-attenuated recombinant measles vaccine candidates expressing the membrane-anchored S protein of SARS-CoV (SARS-CoV-S-vaccine) and they had found that the vaccine could induce highest titers of neutralizing antibodies and protected immunized animals from intranasal infectious challenge with SARS-CoV. Bodmer et al[133] had reported that two live-attenuated measles virus vaccines either expressing S protein or N protein of MERS-CoV could induce robust and multifunctional T cell responses in the mouse model. Frantz et al[134] also mentioned that recombinant measles vaccine could induce stronger and T helper 1-biased responses.

Regarding short-term protection and prevention of viral infection, passive immunotherapy should not be neglected.[135] Monoclonal antibody therapy is one of the best forms of passive immunotherapy. A human IgG1 mAb, CR3014, had been generated and it had been found to be reactive with whole inactivated SARS coronavirus. In addition, CR3014 could be used as prophylaxis for SARS coronavirus infection in ferrets.[136] However, CR3014 was found to be able to block the interaction in parent SARS-CoV strain, but not in escape variants. This led to the ineffectiveness of CR3014 to prevent infection in humans. CR3022 was another monoclonal antibody and it had been found to neutralize CR3014 escape viruses.[136] The combination of CR3014 and CR3022 had also been reported to have the potential to control immune escape.[135] However, the clinical trial of CR3022 with CR3014 had never been tried due to the high cost of manufacturing.

Convalescent plasma can also be called passive immunotherapy. It is usually chosen when there are no specific vaccines or drugs available for emerging infection-related diseases.[137] Arabi et al had tested the feasibility of convalescent plasma therapy as well as its safety and clinical efficacy in critically ill MERS patients. They found that convalescent plasma had an immunotherapeutic potential for the treatment of MERS-CoV infection.[138] In addition, convalescent plasma from recovered SARS patients had also been reported to be useful clinically for treating other SARS patients.[139,140] Importantly, the use of convalescent plasma or serum was also suggested by the World Health Organization under Blood Regulators Network when vaccines and antiviral drugs were unavailable for an emerging virus. In summary, these findings suggest that the current children's RNA-virus-related vaccines are the best alternative methods to be used to vaccinate the uninfected people and health care workers. Convalescent plasma should be routinely used for the treatment of COVID-19 infected critically sick patients if it is available. The avian IBV vaccine is also another choice for clinical trials if its safety has been approved in monkeys. Therefore, we suggest that all the potential interventions be implemented to control the emerging COVID-19 if the infection is uncontrollable.

CONFLICT OF INTERESTS
The authors declare that there are no conflict of interests.

ORCID

Yunhui Liu 🆔 http://orcid.org/0000-0002-9920-9933

REFERENCES

1. Banerjee A, Kulcsar K, Misra V, Frieman M, Mossman K. Bats and coronaviruses. *Viruses*. 2019;11:41. https://doi.org/10.3390/v11010041
2. Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. *Virol J*. 2019;16:69. https://doi.org/10.1186/s12985-019-1182-0
3. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. *Lancet*. 2015;386:995-1007. https://doi.org/10.1016/S0140-6736(15)60454-8
4. Cohen J, Normile D. New SARS-like virus in China triggers alarm. *Science*. 2020;367:234-235. https://doi.org/10.1126/science.367.6475.234
5. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-733. https://doi.org/10.1056/NEJMoa2001017
6. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *New Engl J Med*. 2020;1-9. https://doi.org/10.1056/NEJMoa2001316
7. Chen Y, Liu Q, Guo D. Coronaviruses: genome structure, replication, and pathogenesis. *J Med Virol*. 2020;92(4):418-423. https://doi.org/10.1002/jmv.25681
8. Zhang N, Wang L, Deng X, et al. Recent advances in the detection of respiratory virus infection in humans. *J Med Virol*. 2020;92(4):408-417. https://doi.org/10.1002/jmv.25674
9. Chan JFW, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. *Emerg Microbes Infect*. 2020;9(1):221-236. https://doi.org/10.1080/22221751.2020.1719902
10. Guillin OM, Vindry C, Ohlmann T, Chavatte L. Selenium, selenoproteins and viral infection. *Nutrients*. 2019;11:2101. https://doi.org/10.3390/nu11092101
11. Kantoch M, Litwinska B, Szkoda M, Siennicka J. Importance of vitamin A deficiency in pathology and immunology of viral infections. *Rocz Panstw Zakl Hig*. 2002;53:385-392.
12. Semba RD. Vitamin A and immunity to viral, bacterial and protozoan infections. *Proc Nutr Soc*. 1999;58:719-727. https://doi.org/10.1017/s0029665199000944
13. Villamor E, Mbise R, Spiegelman D, et al. Vitamin A supplements ameliorate the adverse effect of HIV-1, malaria, and diarrheal infections on child growth. *Pediatrics*. 2002;109:e6. https://doi.org/10.1542/peds.109.1.e6
14. Jee J, Hoet AE, Azevedo MP, et al. Effects of dietary vitamin A content on antibody responses of feedlot calves inoculated intramuscularly with an inactivated bovine coronavirus vaccine. *Am J Vet Res*. 2013;74:1353-1362. https://doi.org/10.2460/ajvr.74.10.1353
15. West CE, Sijtsma SR, Kouwenhoven B, Rombout JH, van der Zijpp AJ. Epithelia-damaging virus infections affect vitamin A status in chickens. *J Nutr*. 1992;122:333-339. https://doi.org/10.1093/jn/122.2.333
16. Trottier C, Colombo M, Mann KK, Miller WH Jr., Ward BJ. Retinoids inhibit measles virus through a type I IFN-dependent bystander effect. *FASEB J*. 2009;23:3203-3212. https://doi.org/10.1096/fj.09-129288
17. Powers HJ. Riboflavin (vitamin B-2) and health. *Am J Clin Nutr*. 2003;77:1352-1360. https://doi.org/10.1093/ajcn/77.6.1352
18. Keil SD, Bowen R, Marschner S. Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment. *Transfusion*. 2016;56:2948-2952. https://doi.org/10.1111/trf.13860
19. Kyme P, Thoennissen NH, Tseng CW, et al. C/EBPepsilon mediates nicotinamide-enhanced clearance of *Staphylococcus aureus* in mice. *J Clin Invest*. 2012;122:3316-3329. https://doi.org/10.1172/JCI62070
20. Jones HD, Yoo J, Crother TR, et al. Nicotinamide exacerbates hypoxemia in ventilator-induced lung injury independent of neutrophil infiltration. *PLOS One*. 2015;10:e0123460. https://doi.org/10.1371/journal.pone.0123460
21. Hemila H. Vitamin C and SARS coronavirus. *J Antimicrob Chemother*. 2003;52:1049-1050. https://doi.org/10.1093/jac/dkh002
22. Atherton JG, Kratzing CC, Fisher A. The effect of ascorbic acid on infection chick-embryo ciliated tracheal organ cultures by coronavirus. *Arch Virol*. 1978;56:195-199. https://doi.org/10.1007/bf01317848
23. Field CJ, Johnson IR, Schley PD. Nutrients and their role in host resistance to infection. *J Leukoc Biol*. 2002;71:16-32.
24. Hemila H. Vitamin C intake and susceptibility to pneumonia. *Pediatr Infect Dis J*. 1997;16:836-837. https://doi.org/10.1097/00006454-199709000-00003
25. Tangpricha V, Pearce EN, Chen TC, Holick MF. Vitamin D insufficiency among free-living healthy young adults. *Am J Med*. 2002;112:659-662. https://doi.org/10.1016/s0002-9343(02)01091-4
26. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. *Am J Clin Nutr*. 2004;80:1678S-1688S. https://doi.org/10.1093/ajcn/80.6.1678S
27. Nonnecke BJ, McGill JL, Ridpath JF, Sacco RE, Lippolis JD, Reinhardt TA. Acute phase response elicited by experimental bovine diarrhea virus (BVDV) infection is associated with decreased vitamin D and E status of vitamin-replete preruminant calves. *J Dairy Sci*. 2014;97:5566-5579. https://doi.org/10.3168/jds.2014-8293
28. Galmes S, Serra F, Palou A. Vitamin E metabolic effects and genetic variants: a challenge for precision nutrition in obesity and associated disturbances. *Nutrients*. 2018;10:1919. https://doi.org/10.3390/nu10121919
29. Beck MA, Kolbeck PC, Rohr LH, Shi Q, Morris VC, Levander OA. Vitamin E deficiency intensifies the myocardial injury of coxsackievirus B3 infection of mice. *J Nutr*. 1994;124:345-358. https://doi.org/10.1093/jn/124.3.345
30. Beck MA. Increased virulence of coxsackievirus B3 in mice due to vitamin E or selenium deficiency. *J Nutr*. 1997;127:966S-970S. https://doi.org/10.1093/jn/127.5.966S
31. Cai C, Koch B, Morikawa K, et al. Macrophage-derived extracellular vesicles induce long-lasting immunity against hepatitis C virus which is blunted by polyunsaturated fatty acids. *Front Immunol*. 2018;9:723. https://doi.org/10.3389/fimmu.2018.00723
32. Begin ME, Manku MS, Horrobin DF. Plasma fatty acid levels in patients with acquired immune deficiency syndrome and in controls. *Prostaglandins Leukot Essent Fatty Acids*. 1989;37:135-137. https://doi.org/10.1016/0952-3278(89)90110-5
33. Morita M, Kuba K, Ichikawa A, et al. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. *Cell*. 2013;153:112-125. https://doi.org/10.1016/j.cell.2013.02.027
34. Leu GZ, Lin TY, Hsu JT. Anti-HCV activities of selective polyunsaturated fatty acids. *Biochem Biophys Res Commun*. 2004;318:275-280. https://doi.org/10.1016/j.bbrc.2004.04.019
35. Rayman MP. Selenium and human health. *Lancet*. 2012;379:1256-1268. https://doi.org/10.1016/S0140-6736(11)61452-9
36. Beck MA, Matthews CC. Micronutrients and host resistance to viral infection. *Proc Nutr Soc*. 2000;59:581-585. https://doi.org/10.1017/s0029665100000823
37. Harthill M. Review: micronutrient selenium deficiency influences evolution of some viral infectious diseases. *Biol Trace Elem Res*. 2011;143:1325-1336. https://doi.org/10.1007/s12011-011-8977-1
38. Beck MA, Nelson HK, Shi Q, et al. Selenium deficiency increases the pathology of an influenza virus infection. *FASEB J*. 2001;15:1481-1483
39. Beck MA, Shi Q, Morris VC, Levander OA. Rapid genomic evolution of a non-virulent coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates. *Nat Med*. 1995;1:433-436. https://doi.org/10.1038/nm0595-433

40. Ma X, Bi S, Wang Y, Chi X, Hu S. Combined adjuvant effect of ginseng stem-leaf saponins and selenium on immune responses to a live bivalent vaccine of Newcastle disease virus and infectious bronchitis virus in chickens. *Poult Sci*. 2019;98:3548-3556. https://doi.org/10.3382/ps/pez207

41. Maares M, Haase H. Zinc and immunity: an essential interrelation. *Arch Biochem Biophys*. 2016;611:58-65. https://doi.org/10.1016/j.abb.2016.03.022

42. Tuerk MJ, Fazel N. Zinc deficiency. *Curr Opin Gastroenterol*. 2009;25:136-143. https://doi.org/10.1097/MOG.0b013e328321b395

43. Awotiwon AA, Oduwole O, Sinha A, Okwundu CI. Zinc supplementation for the treatment of measles in children. *Cochrane Database Syst Rev*. 2017;2017(6):CD011177. https://doi.org/10.1002/14651858.CD011177.pub3

44. te Velthuis AJW, van den Worm SHE, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. *PLOS Pathog*. 2010;6:e1001176. https://doi.org/10.1371/journal.ppat.1001176

45. Wessling-Resnick M. Crossing the iron gate: why and how transferrin receptors mediate viral entry. *Annu Rev Nutr*. 2018;38:431-458. https://doi.org/10.1146/annurev-nutr-082117-051749

46. Jayaweera J, Reyes M, Joseph A. Childhood iron deficiency anemia leads to recurrent respiratory tract infections and gastroenteritis. *Sci Rep*. 2019;9:12637. https://doi.org/10.1038/s41598-019-49122-z

47. Pei J, Sekellick MJ, Marcus PI, Choi IS, Collisson EW. Chicken interferon type I inhibits infectious bronchitis virus replication and associated respiratory illness. *J Interferon Cytokine Res*. 2001;21:1071-1077. https://doi.org/10.1089/107999001317205204

48. Turner RB, Felton A, Kosak K, Kelsey DK, Meschievitz CK. Prevention of experimental coronavirus colds with intranasal alpha-2b interferon. *J Infect Dis*. 1986;154:443-447. https://doi.org/10.1093/infdis/154.3.443

49. Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J Jr. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. *Biochem Biophys Res Commun*. 2005;326:905-908. https://doi.org/10.1016/j.bbrc.2004.11.128

50. Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. *J Clin Virol*. 2004;31:69-75. https://doi.org/10.1016/j.jcv.2004.03.003

51. Kuri T, Zhang X, Habjan M, et al. Interferon priming enables cells to partially overturn the SARS coronavirus-induced block in innate immune activation. *J Gen Virol*. 2009;90:2686-2694. https://doi.org/10.1099/vir.0.013599-0

52. Tan ELC, Ooi EE, Lin CY, et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. *Emerg Infect Dis*. 2004;10:581-586. https://doi.org/10.3201/eid1004.030458

53. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet*. 2001;358:958-965. https://doi.org/10.1016/s0140-6736(01)06102-5

54. Haagmans BL, Kuiken T, Martina BE, et al. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. *Nat Med*. 2004;10:290-293. https://doi.org/10.1038/nm1001

55. Bijlenga G. Proposal for vaccination against SARS coronavirus using avian infectious bronchitis virus strain H from The Netherlands. *J Infect*. 2005;51:263-265. https://doi.org/10.1016/j.jinf.2005.04.010

56. Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. *JAMA*. 2003;290:3222-3228. https://doi.org/10.1001/jama.290.24.3222

57. Mustafa S, Balkhy H, Gabere MN. Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): a review. *J Infect Public Health*. 2018;11:9-17. https://doi.org/10.1016/j.jiph.2017.08.009

58. Bussel JB, Szatrowski TP. Uses of intravenous gammaglobulin in immune hematologic disease. *Immunol Invest*. 1995;24:451-456. https://doi.org/10.3109/08820139509062794

59. Lew TWK. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. *JAMA*. 2003;290:374-380. https://doi.org/10.1001/jama.290.3.374

60. Dalakas MC, Clark WM. Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. *Neurology*. 2003;60:1736-1737. https://doi.org/10.1212/01.wnl.0000074394.15882.83

61. Matteucci C, Grelli S, Balestrieri E, et al. Thymosin alpha 1 and HIV-1: recent advances and future perspectives. *Future Microbiol*. 2017;12:141-155. https://doi.org/10.2217/fmb-2016-0125

62. Costantini C, Bellet MM, Pariano M, et al. A reappraisal of thymosin alpha1 in cancer therapy. *Front Oncol*. 2019;9:873. https://doi.org/10.3389/fonc.2019.00873

63. Pica F, Gaziano R, Casalinuovo IA, et al. Serum thymosin alpha 1 levels in normal and pathological conditions. *Expert Opin Biol Ther*. 2018;18:13-21. https://doi.org/10.1080/14712598.2018.1474197

64. Baumann CA, Badamchian M, Goldstein AL. Thymosin alpha 1 antagonizes dexamethasone and CD3-induced apoptosis of CD4+ CD8+ thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways. *Mech Ageing Dev*. 1997;94:85-101. https://doi.org/10.1016/s0047-6374(96)01860-x

65. Gao ZC, Zhu JH, Sun Y, et al. Clinical investigation of outbreak of nosocomial severe acute respiratory syndrome. *Zhongguo Wei Zhong Bing Ji Jiu Yi Xue*. 2003;15:332-335

66. Kumar V, Jung YS, Liang PH. Anti-SARS coronavirus agents: a patent review (2008-present). *Expert Opin Ther Pat*. 2013;23:1337-1348. https://doi.org/10.1517/13543776.2013.823159

67. Duchateau J, Servais G, Vreyens R, Delespesse G, Bolla K. Modulation of immune response in aged humans through different administration modes of thymopentin. *Surv Immunol Res*. 1985;4(suppl 1):94-101.

68. Duchateau J, Delespesse G, Bolla K. Phase variation in the modulation of the human immune response. *Immunol Today*. 1983;4:213-214. https://doi.org/10.1016/0167-5699(83)90028-2

69. Zaruba K, Rastorfer M, Grob PJ, Joller-Jemelka H, Bolla K. Thymopentin as adjuvant in non-responders or hyporesponders to hepatitis B vaccination. *Lancet*. 1983;2:1245. https://doi.org/10.1016/s0140-6736(83)91284-9

70. Renoux G. The general immunopharmacology of levamisole. *Drugs*. 1980;20:89-99. https://doi.org/10.2165/00003495-198020020-00001

71. Joffe MI, Sukha NR, Rabson AR. Lymphocyte subsets in measles. Depressed helper/inducer subpopulation reversed by in vitro treatment with levamisole and ascorbic acid. *J Clin Invest*. 1983;72:971-980. https://doi.org/10.1172/JCI111069

72. Ziaei M, Ziaei F, Manzouri B. Systemic cyclosporine and corneal transplantation. *Int Ophthalmol*. 2016;36:139-146. https://doi.org/10.1007/s10792-015-0137-8

73. Luo C, Luo H, Zheng S, et al. Nucleocapsid protein of SARS coronavirus tightly binds to human cyclophilin A. *Biochem Biophys Res Commun*. 2004;321:557-565. https://doi.org/10.1016/j.bbrc.2004.07.003

74. Dawar FU, Tu J, Khattak MN, et al. Factor in virus replication and potential target for anti-viral therapy. *Curr Issues Mol Biol*. 2017;21:1-20. https://doi.org/10.21775/cimb.021.001

75. Pfefferle S, Schöpf J, Kögl M, et al. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. *PLOS Pathog*. 2011;7:e1002331. https://doi.org/10.1371/journal.ppat.1002331

76. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr H. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. *Lancet*. 2003;361:2045-2046. https://doi.org/10.1016/s0140-6736(03)13615-x

77. Park JY, Jeong HJ, Kim JH, et al. Diarylheptanoids from *Alnus japonica* inhibit papain-like protease of severe acute respiratory syndrome coronavirus. *Biol Pharm Bull*. 2012;35:2036-2042. https://doi.org/10.1248/bpb.b12-00623

78. Chen L, Gui C, Luo X, et al. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. *J Virol*. 2005;79:7095-7103. https://doi.org/10.1128/JVI.79.11.7095-7103.2005

79. Panche AN, Diwan AD, Chandra SR. Flavonoids: an overview. *J Nutr Sci*. 2016;5:e47. https://doi.org/10.1017/jns.2016.41

80. Shimizu JF, Lima CS, Pereira CM, et al. Flavonoids from pterogyne nitens inhibit hepatitis C virus entry. *Sci Rep*. 2017;7(1):16127. https://doi.org/10.1038/s41598-017-16336-y

81. Jo S, Kim S, Shin DH, Kim MS. Inhibition of SARS-CoV 3CL protease by flavonoids. *J Enzyme Inhib Med Chem*. 2020;35:145-151. https://doi.org/10.1080/14756366.2019.1690480

82. Jo S, Kim H, Kim S, Shin DH, Kim MS. Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors. *Chem Biol Drug Des*. 2019;94:2023-2030. https://doi.org/10.1111/cbdd.13604

83. Ryu YB, Jeong HJ, Kim JH, et al. Biflavonoids from *Torreya nucifera* displaying SARS-CoV 3CL(pro) inhibition. *Bioorg Med Chem*. 2010;18:7940-7947. https://doi.org/10.1016/j.bmc.2010.09.035

84. Warner FJ, Smith AI, Hooper NM, Turner AJ. Angiotensin-converting enzyme-2: a molecular and cellular perspective. *Cell Mol Life Sci*. 2004;61:2704-2713. https://doi.org/10.1007/s00018-004-4240-7

85. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature*. 2003;426:450-454. https://doi.org/10.1038/nature02145

86. Dimitrov DS. The secret life of ACE2 as a receptor for the SARS virus. *Cell*. 2003;115:652-653. https://doi.org/10.1016/s0092-8674(03)00976-0

87. Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. *Proc Natl Acad Sci USA*. 2004;101:4240-4245. https://doi.org/10.1073/pnas.0306446101

88. Yeung KS, Yamanaka GA, Meanwell NA. Severe acute respiratory syndrome coronavirus entry into host cells: Opportunities for therapeutic intervention. *Med Res Rev*. 2006;26:414-433. https://doi.org/10.1002/med.20055

89. Sui J, Li W, Murakami A, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. *Proc Natl Acad Sci USA*. 2004;101:2536-2541. https://doi.org/10.1073/pnas.0307140101

90. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? *Lancet Infect Dis*. 2003;3:722-727. https://doi.org/10.1016/s1473-3099(03)00806-5

91. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. *Virol J*. 2005;2:69. https://doi.org/10.1186/1743-422X-2-69

92. Alves DS, Perez-Fons L, Estepa A, Micol V. Membrane-related effects underlying the biological activity of the anthraquinones emodin and barbaloin. *Biochem Pharmacol*. 2004;68:549-561. https://doi.org/10.1016/j.bcp.2004.04.012

93. Ho TY, Wu SL, Chen JC, Li CC, Hsiang CY. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. *Antiviral Res*. 2007;74:92-101. https://doi.org/10.1016/j.antiviral.2006.04.014

94. Zhang XW, Yap YL. Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs. *Bioorg Med Chem*. 2004;12:2517-2521. https://doi.org/10.1016/j.bmc.2004.03.035

95. Trampczynska A, Bottcher C, Clemens S. The transition metal chelator nicotianamine is synthesized by filamentous fungi. *FEBS Lett*. 2006;580:3173-3178. https://doi.org/10.1016/j.febslet.2006.04.073

96. Takahashi S, Yoshiya T, Yoshizawa-Kumagaye K, Sugiyama T. Nicotianamine is a novel angiotensin-converting enzyme 2 inhibitor in soybean. *Biomed Res*. 2015;36:219-224. https://doi.org/10.2220/biomedres.36.219

97. Wenzel RP, Edmond MB. Managing SARS amidst uncertainty. *N Engl J Med*. 2003;348:1947-1948. https://doi.org/10.1056/NEJMp030072

98. Cyranoski D. Critics slam treatment for SARS as ineffective and perhaps dangerous. *Nature*. 2003;423:4. https://doi.org/10.1038/423004a

99. Booth CM. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. *JAMA*. 2003;289:2801-2809. https://doi.org/10.1001/jama.289.21.JOC30885

100. Tsang K, Zhong NS. SARS: pharmacotherapy. *Respirology*. 2003;8(suppl):S25-S30. https://doi.org/10.1046/j.1440-1843.2003.00525.x

101. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. *Nat Commun*. 2020;11:222. https://doi.org/10.1038/s41467-019-13940-6

102. Chu CM. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. *Thorax*. 2004;59:252-256. https://doi.org/10.1136/thorax.2003.012658

103. Kim UJ, Won EJ, Kee SJ, Jung SI, Jang HC. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome. *Antivir Ther*. 2016;21:455-459. https://doi.org/10.3851/IMP3002

104. Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. *mBio*. 2018;9(2):e00221-18. https://doi.org/10.1128/mBio.00221-18

105. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. *N Engl J Med*. 2020:NEJMoa2001191. https://doi.org/10.1056/NEJMoa2001191

106. Jarvis B, Faulds D. Nelfinavir. A review of its therapeutic efficacy in HIV infection. *Drugs*. 1998;56:147-167. https://doi.org/10.2165/00003495-199856010-00013

107. Yamamoto N, Yang R, Yoshinaka Y, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. *Biochem Biophys Res Commun*. 2004;318:719-725. https://doi.org/10.1016/j.bbrc.2004.04.083

108. Blaising J, Polyak SJ, Pecheur EI. Arbidol as a broad-spectrum antiviral: an update. *Antiviral Res*. 2014;107:84-94. https://doi.org/10.1016/j.antiviral.2014.04.006

109. Boriskin YS, Leneva IA, Pecheur EI, Polyak SJ. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. *Curr Med Chem*. 2008;15:997-1005. https://doi.org/10.2174/092986708784049658

110. Pécheur EI, Borisevich V, Halfmann P, et al. The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses. *J Virol*. 2016;90:3086-3092. https://doi.org/10.1128/JVI.02077-15

111. Khamitov RA, Loginova S, Shchukina VN, Borisevich SV, Maksimov VA, Shuster AM. [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures]. *Vopr Virusol*. 2008;53:9-13

112. Robbins RA, Grisham MB. Nitric oxide. *Int J Biochem Cell Biol*. 1997;29:857-860. https://doi.org/10.1016/s1357-2725(96)00167-7

113. Barnes PJ. Nitric oxide and airway disease. *Ann Med*. 1995;27:389-393. https://doi.org/10.3109/07853899509002592

114. Rossaint R, Gerlach H, Schmidt-Ruhnke H, et al. Efficacy of inhaled nitric oxide in patients with severe ARDS. *Chest*. 1995;107:1107-1115. https://doi.org/10.1378/chest.107.4.1107

115. Hui DS. An overview on severe acute respiratory syndrome (SARS). *Monaldi Arch Chest Dis.* 2005;63:149-157. https://doi.org/10.4081/monaldi.2005.632

116. Akerstrom S, Mousavi-Jazi M, Klingstrom J, Leijon M, Lundkvist A, Mirazimi A. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. *J Virol.* 2005;79:1966-1969. https://doi.org/10.1128/JVI.79.3.1966-1969.2005

117. Sachse G, Willms B. Efficacy of thioctic acid in the therapy of peripheral diabetic neuropathy. *Horm Metab Res Suppl.* 1980;9:105-107.

118. Tibullo D, Li Volti G, Giallongo C, et al. Biochemical and clinical relevance of alpha lipoic acid: antioxidant and anti-inflammatory activity, molecular pathways and therapeutic potential. *Inflamm Res.* 2017;66:947-959. https://doi.org/10.1007/s00011-017-1079-6

119. El-Senousey HK, Chen B, Wang JY, Atta AM, Mohamed FR, Nie QH. Effects of dietary vitamin C, vitamin E, and alpha-lipoic acid supplementation on the antioxidant defense system and immune-related gene expression in broilers exposed to oxidative stress by dexamethasone. *Poult Sci.* 2018;97:30-38. https://doi.org/10.3382/ps/pex298

120. Wu YH, Tseng CP, Cheng ML, Ho HY, Shih SR, Chiu DTY. Glucose-6-phosphate dehydrogenase deficiency enhances human coronavirus 229E infection. *J Infect Dis.* 2008;197:812-816. https://doi.org/10.1086/528377

121. Baur A, Harrer T, Peukert M, Jahn G, Kalden JR, Fleckenstein B. Alpha-lipoic acid is an effective inhibitor of human immuno-deficiency virus (HIV-1) replication. *Klin Wochenschr.* 1991;69:722-724. https://doi.org/10.1007/bf01649442

122. Marriott I, Huet-Hudson YM. Sexual dimorphism in innate immune responses to infectious organisms. *Immunol Res.* 2006;34:177-192. https://doi.org/10.1385/IR:34:3:177

123. Karlberg J, Chong DS, Lai WY. Do men have a higher case fatality rate of severe acute respiratory syndrome than women do? *Am J Epidemiol.* 2004;159:229-231. https://doi.org/10.1093/aje/kwh056

124. Leong HN, Earnest A, Lim HH, et al. SARS in Singapore--predictors of disease severity. *Ann Acad Med Singapore.* 2006;35:326-331.

125. Alghamdi I, Hussain I, Alghamdi M, Almalki S, Alghamdi M, Elsheemy M. The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health. *Int J Gen Med.* 2014;7:417-423. https://doi.org/10.2147/IJGM.S67061

126. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection. *J Immunol.* 2017;198:4046-4053. https://doi.org/10.4049/jimmunol.1601896

127. Wei L, Sun S, Zhang J, et al. Endocrine cells of the adenohypophysis in severe acute respiratory syndrome (SARS). *Biochem Cell Biol.* 2010;88:723-730. https://doi.org/10.1139/O10-022

128. Peretz J, Pekosz A, Lane AP, Klein SL. Estrogenic compounds reduce influenza A virus replication in primary human nasal epithelial cells derived from female, but not male, donors. *Am J Physiol Lung Cell Mol Physiol.* 2016;310:L415-L425. https://doi.org/10.1152/ajplung.00398.2015

129. Lin SC, Ho CT, Chuo WH, Li S, Wang TT, Lin CC. Effective inhibition of MERS-CoV infection by resveratrol. *BMC Infect Dis.* 2017;17:144. https://doi.org/10.1186/s12879-017-2253-8

130. Li Q, Zhao Z, Zhou D, et al. Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. *Peptides.* 2011;32:1518-1525. https://doi.org/10.1016/j.peptides.2011.05.015

131. Cavanagh D. Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus. *Avian Pathol.* 2003;32:567-582. https://doi.org/10.1080/03079450310001621198

132. Escriou N, Callendret B, Lorin V, et al. Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein. *Virology.* 2014;452-453:32-41. https://doi.org/10.1016/j.virol.2014.01.002

133. Bodmer BS, Fiedler AH, Hanauer JRH, Prufer S, Muhlebach MD. Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model. *Virology.* 2018;521:99-107. https://doi.org/10.1016/j.virol.2018.05.028

134. Frantz PN, Teeravechyan S, Tangy F. Measles-derived vaccines to prevent emerging viral diseases. *Microbes Infect.* 2018;20:493-500. https://doi.org/10.1016/j.micinf.2018.01.005

135. ter Meulen J, van den Brink EN, Poon LLM, et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. *PLOS Med.* 2006;3:e237. https://doi.org/10.1371/journal.pmed.0030237

136. ter Meulen J, Bakker AB, van den Brink EN, et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. *Lancet.* 2004;363:2139-2141. https://doi.org/10.1016/S0140-6736(04)16506-9

137. Marano G, Vaglio S, Pupella S, et al. Convalescent plasma: new evidence for an old therapeutic tool? *Blood Transfus.* 2016;14:152-157. https://doi.org/10.2450/2015.0131-15

138. Arabi Y, Balkhy H, Hajeer AH, et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. *Springerplus.* 2015;4:709. https://doi.org/10.1186/s40064-015-1490-9

139. Cheng Y, Wong R, Soo YOY, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. *Eur J Clin Microbiol Infect Dis.* 2005;24:44-46. https://doi.org/10.1007/s10096-004-1271-9

140. Soo YOY, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. *Clin Microbiol Infect.* 2004;10:676-678. https://doi.org/10.1111/j.1469-0691.2004.00956.x